Highlighted
Results for the Second Quarter and First Half 2025
Aug 20, 2025
Another strong quarter for sales revenues with 16.7 % growth, ending at MNOK 169.1 (MNOK 144.9). Record sales revenue for the first half year with 25.8 % growth, ending at MNOK 350.6 (MNOK 278.7).
Results for the First Quarter 2025
May 9, 2025
An exceptionally strong quarter for sales revenues, 20.1 % above the previous record, ending at MNOK 181.5. This is growth of 35.7 % compared to first quarter last year (MNOK 133.8).
Medistim Strengthens its Commercial Operations
Jan 31, 2025
Medistim announces the strengthening of its commercial operations
Medistim launches clinical study on TTFM and HFUS in Vascular surgery
Nov 15, 2024
On November 14th Medistim announced the launch of the PATENT study, an open, prospective, multicenter trial aimed at evaluating the immediate clinical benefits and long-term prognostic value of intraoperative completion control using transit time flow measurement (TTFM) and high-frequency ultrasound (HFUS) imaging.
Medistim Announces Launch of MiraQ INTUI Software Platform
Nov 11, 2024
The company is pleased to announce the successful completion of its Early Access program for the new MiraQ™ INTUI software platform. The official product launch is set for December 13 at the International Coronary Congress (ICC) in London.
.png)
Medistim to host a Capital Markets Day on Monday, December 16th 2024
Nov 8, 2024
Medistim to host Capital Markets Day 2024
Medistim receives EU MDR certificates for MiraQ systems and TTFM probes
Oct 18, 2024
After years of preparation, Medistim has successfully obtained its first CE certificates under the latest EU Medical Device Regulation (EU MDR 2017/745).
